Research into Peptides
Your direct source for raw data, clinical breakdowns, and industry updates on the frontier of peptide science.
*For research purposes only - not for human consumption*
Body Composition Research
Structural Targeting of Fat Vasculature and Apoptotic Kinetics with Adipotide (FTPP)
This preclinical mechanical study maps the exact cellular binding physics of Adipotide, tracking how it utilises a homing sequence to find fat tissue and a toxic payload to destroy it.
Stimulation of Lipolysis and the Inhibition of Adipogenesis with AOD-9604
This preclinical mechanical study maps the exact cellular behaviour of the fragment, tracking how it forces mature fat cells to release stored energy while actively blocking the formation of new fat tissue.
A Phase IIb Randomized, Double-Blind, Placebo-Controlled Human Trial of the Lipolytic Oligopeptide AOD9604 for the Management of Overweight and Obesity Profiles
This randomised, double-blind human trial evaluated the safety, tolerability, and fat-burning efficacy of varying daily oral doses of the 176-191 fragment (AOD9604) in obese human subjects.
Pharmacological Activation of the AMPK Pathway as a Driver of Adaptive Mitochondrial Biogenesis and Endurance Performance
This is the landmark study that made AICAR famous worldwide, earning it the nickname "exercise in a pill."
Muscle Performance and Enhanced Recovery (5-Amino-1MQ)
This study evaluated how the compound impacts aging muscle and exercise dynamics.
Biomarker Correlation in Obesity and Insulin Resistance (Observational)
This trial analysed how metabolic dysfunction impacts baseline circulating MOTS-c levels in human adults.
The Phase 2 Retatrutide Obesity Trial
Retatrutide (initially known in preclinical research under the code name LY3437943) is a first-in-class triple hormone receptor agonist (Jastreboff et al., 2023). It targets the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon simultaneously (Jastreboff et al., 2023).
Preclinical Weight Loss & Synergy Efficacy (AM833 + Semaglutide)
This foundational study evaluated the impact of cagrilintide alone and in combination with a GLP-1 receptor agonist on metabolic markers in rodents.